

Resource Summary Report

Generated by [RRID](#) on Sep 6, 2026

94T778

RRID:CVCL_U613

Type: Cell Line

Proper Citation

RRID:CVCL_U613

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_U613

Proper Citation: RRID:CVCL_U613

Description: Cell line 94T778 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Female

Disease: Atypical lipomatous tumor/well differentiated liposarcoma

Defining Citation: [PMID:18823700](#), [PMID:29279323](#)

Comments: Population: Caucasian., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: 94T778

Cross References: ArrayExpress:E-MTAB-5625, ATCC:CRL-3044, cancercellines:CVCL_U613, Cell_Model_Passport:SIDM01897, DepMap:ACH-001795, Wikidata:Q54605787

ID: CVCL_U613

Record Creation Time: 20220427T215103+0000

Record Last Update: 20260905T184346+0000

Ratings and Alerts

No rating or validation information has been found for 94T778.

No alerts have been found for 94T778.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 4 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Dumbrava EE, et al. (2025) Milademetan in Advanced Solid Tumors with MDM2 Amplification and Wild-type TP53: Preclinical and Phase II Clinical Trial Results. Clinical cancer research : an official journal of the American Association for Cancer Research, 31(20), 4255.

Ludwig MP, et al. (2023) Proteasome Inhibition Sensitizes Liposarcoma to MDM2 Inhibition with Nutlin-3 by Activating the ATF4/CHOP Stress Response Pathway. Cancer research, 83(15), 2543.

Toivanen K, et al. (2023) PDE3A Is a Highly Expressed Therapy Target in Myxoid Liposarcoma. Cancers, 15(22).

Szwarc MM, et al. (2023) FAM193A is a positive regulator of p53 activity. Cell reports, 42(3), 112230.